Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 4
1991 2
1992 4
1993 6
1994 7
1995 13
1996 6
1997 28
1998 25
1999 39
2000 61
2001 28
2002 57
2003 52
2004 40
2005 47
2006 73
2007 63
2008 84
2009 85
2010 101
2011 114
2012 102
2013 113
2014 97
2015 96
2016 91
2017 84
2018 73
2019 59
2020 65
2021 81
2022 79
2023 18
Text availability
Article attribute
Article type
Publication date

Search Results

1,704 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
The primary aim of this study was to compare the efficacy of potent nonergoline dopamine agonists pramipexole and ropinirole in both "dopamine agonist monotherapy group" and "levodopa add-on therapy group" in Parkinson's disease. ...CONCLUSION: This study supports t …
The primary aim of this study was to compare the efficacy of potent nonergoline dopamine agonists pramipexole and ropinirole in both …
[Pramipexole in bipolar depression: a literature review and clinical recommendations].
Dionys V, Sienaert P. Dionys V, et al. Tijdschr Psychiatr. 2021;63(9):658-664. Tijdschr Psychiatr. 2021. PMID: 34647304 Free article. Review. Dutch.
A second RCT reported higher response and remission results with pramipexole compared to placebo (60% vs. 9%, 40% vs. 9%). Pramipexole was generally well tolerated. CONCLUSION: The use of pramipexole in treatment resistant bipolar depression appears promising …
A second RCT reported higher response and remission results with pramipexole compared to placebo (60% vs. 9%, 40% vs. 9%). Pramipe
Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis.
Tundo A, de Filippis R, De Crescenzo F. Tundo A, et al. Acta Psychiatr Scand. 2019 Aug;140(2):116-125. doi: 10.1111/acps.13055. Epub 2019 Jun 9. Acta Psychiatr Scand. 2019. PMID: 31111467
Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. METHODS: We conducted a systematic review of randomized clinical trials (RCTs) and observational studies on pramipexole for patients with major depre …
Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. METHODS: We cond …
Pramipexole to Improve Cognition in Bipolar Disorder: A Randomized Controlled Trial.
Van Meter AR, Perez-Rodriguez MM, Braga RJ, Shanahan M, Hanna L, Malhotra AK, Burdick KE. Van Meter AR, et al. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):421-427. doi: 10.1097/JCP.0000000000001407. J Clin Psychopharmacol. 2021. PMID: 33956703 Free PMC article. Clinical Trial.
All had stable mood and clinically significant neurocognitive impairment at baseline. Participants were randomized to receive pramipexole (n = 31) or a placebo (n = 29), dose was initiated at 0.125 mg 2 times a day and increased to a target of 4.5 mg/d. RESULTS: At trial e …
All had stable mood and clinically significant neurocognitive impairment at baseline. Participants were randomized to receive pramipexole
Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.
Wei SZ, Yao XY, Wang CT, Dong AQ, Li D, Zhang YT, Ren C, Zhang JB, Mao CJ, Wang F, Liu CF. Wei SZ, et al. Brain Res Bull. 2021 Dec;177:363-372. doi: 10.1016/j.brainresbull.2021.10.015. Epub 2021 Oct 24. Brain Res Bull. 2021. PMID: 34699917
Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. ...Pramipexole significantly improved depression-like behavior in DRD2(-/-) mice but not in DRD3(-/-) mice. ...
Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. ...Pramipexole significantly
Classics in Chemical Neuroscience: Pramipexole.
Wilson SM, Wurst MG, Whatley MF, Daniels RN. Wilson SM, et al. ACS Chem Neurosci. 2020 Sep 2;11(17):2506-2512. doi: 10.1021/acschemneuro.0c00332. Epub 2020 Aug 17. ACS Chem Neurosci. 2020. PMID: 32786316 Review.
Pramipexole is a unique compound in its therapeutic potential because it has D(3)-preferring properties. ...Currently, pramipexole is approved to treat signs and symptoms of idiopathic Parkinson's disease and moderate to severe symptoms of primary restless le
Pramipexole is a unique compound in its therapeutic potential because it has D(3)-preferring properties. ...Currently, pramipexole
Iron for the treatment of restless legs syndrome.
Trotti LM, Becker LA. Trotti LM, et al. Cochrane Database Syst Rev. 2019 Jan 4;1(1):CD007834. doi: 10.1002/14651858.CD007834.pub3. Cochrane Database Syst Rev. 2019. PMID: 30609006 Free PMC article.
Nine studies compared iron to placebo and one study compared iron to a dopamine agonist (pramipexole). The possibility for bias among the trials was variable. ...We are uncertain whether iron therapy improves quality of life in comparison to placebo. Iron therapy may make …
Nine studies compared iron to placebo and one study compared iron to a dopamine agonist (pramipexole). The possibility for bias among …
[Othello syndrome].
Esteban-Jiménez Ó, Navarro-Pemán C, González-Rubio F. Esteban-Jiménez Ó, et al. Semergen. 2016 Jan-Feb;42(1):63-5. doi: 10.1016/j.semerg.2014.10.016. Epub 2014 Dec 12. Semergen. 2016. PMID: 25510590 Spanish. No abstract available.
Striatal mechanism of the restless legs syndrome.
Lai YY, Hsieh KC, Chew KT, Nguyen D, Siegel JM. Lai YY, et al. Sleep. 2022 Jul 11;45(7):zsac110. doi: 10.1093/sleep/zsac110. Sleep. 2022. PMID: 35537196
After baseline recording, striatal-lesioned wild-type (WT-STL) and striatal-lesioned iron-deficient (ID-STL) rats were given pramipexole and thioperamide injections. Iron-deficient and ID-STL rats were then given a standard rodent diet for 4 weeks, and their sleep and moto …
After baseline recording, striatal-lesioned wild-type (WT-STL) and striatal-lesioned iron-deficient (ID-STL) rats were given pramipexole
Pramipexole associated dystonia.
Pandey S, Sarma N, Jain S. Pandey S, et al. Parkinsonism Relat Disord. 2017 May;38:104-105. doi: 10.1016/j.parkreldis.2017.03.003. Epub 2017 Mar 7. Parkinsonism Relat Disord. 2017. PMID: 28291594 No abstract available.
1,704 results